Type and hit ENTER

ProAxsis specialises in four key areas of business:

NEATstik®
Neutrophil Elastase Airways Test
  • Rapid point-of-care tests – NEATstik®, a lateral flow test for measuring active neutrophil elastase at point-of-care, was registered with a CE Mark in September 2017.
Clinical research services
Academic and Pharmaceutical Company Researchers
  • Our experienced team can provide a number of services for both academic and pharmaceutical company researchers, and are able to offer sample analysis at our purpose-built laboratory for a range of proteases and other inflammatory biomarkers.
ProAxsis R&D Projects
are supported by a variety of external partners
  • ProAxsis has a number of R&D projects ongoing, whch are supported by a variety of external partners. We are also able to conduct bespoke R&D projects at the request of academic groups or pharmaceutical companies.

NEWS

ProAxsis confirms that new data on its ProteaseTag® technology will be presented at the American Thoracic Society Conference, which takes place between May 19th-24th in San Diego. The University of Oxford team will be presenting data on NEATstik®, a novel point-of-care test for monitoring active neutrophil elastase …

May 2, 2018

ProAxsis is proud to be collaborating with Dr. Gunnar Schroeder and Prof. Cliff Taggart from the School of Medicine, Dentistry and Biomedical Science at Queen’s University Belfast, as part of the Horizon 2020-funded Marie Skłodowska-Curie doctoral training (SPaRK) programme. The SPaRK Programme is driven by the need …

March 6, 2018

Following on from the commercialisation update provided in November, ProAxsis is pleased to report the first sale of NEATstik®, the company’s novel sputum-based point-of-care test, to a research laboratory conducting an ongoing respiratory clinical trial for a pharmaceutical company. NEATstik® was registered with a CE Mark in the …

February 15, 2018
GET CONNECTED
RECENT POSTS
ABOUT US
TECHNOLOGY
SERVICES
ProAxsis | developing products for the capture, detection and measurement of active protease biomarkers of disease